Response to Erlotinib in a Patient with Compound EGFR L747S and Exon 19 Deletion

Letter/Communication

Open access

Umang Swami, Deqin Ma and Jun Zhang

Journal of thoracic oncology, Vol.13(7), pp.e129-e130

07/2018

DOI: 10.1016/j.jtho.2018.03.034

PMID: 29935854

Files and links (1)

url

https://doi.org/10.1016/j.jtho.2018.03.034View

Published (Version of record) Open Access

Mutation

Lung Neoplasms - genetics

Lung Neoplasms - drug therapy

Sequence Deletion

Adenocarcinoma - pathology

Prognosis

Exons

Humans

ErbB Receptors - genetics

Lung Neoplasms - pathology

Male

Antineoplastic Agents - therapeutic use

Adenocarcinoma - drug therapy

Adenocarcinoma - genetics

Erlotinib Hydrochloride - therapeutic use

Title: Subtitle: Response to Erlotinib in a Patient with Compound EGFR L747S and Exon 19 Deletion
Creators: Umang Swami - Division of Hematology, Oncology and Blood and Marrow Transplantation, Department of Internal Medicine, Holden Comprehensive Cancer Center, University of Iowa Carver College of Medicine, Iowa City, Iowa
Deqin Ma - Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, Iowa
Jun Zhang - Division of Hematology, Oncology and Blood and Marrow Transplantation, Department of Internal Medicine, Holden Comprehensive Cancer Center, University of Iowa Carver College of Medicine, Iowa City, Iowa. Electronic address: jun-zhang-1@uiowa.edu
Resource Type: Letter/Communication
Publication Details: Journal of thoracic oncology, Vol.13(7), pp.e129-e130
Publisher: United States
DOI: 10.1016/j.jtho.2018.03.034
PMID: 29935854
ISSN: 1556-0864
eISSN: 1556-1380
Grant note: DOI: 10.13039/100000048, name: American Cancer Society, award: IRG-15-176-40
Language: English
Date published: 07/2018
Academic Unit: Pathology; Internal Medicine
Record Identifier: 9984047766902771

22 Record Views